Sure, having a cold or respiratory infection can temporarily make it harder to breathe. But if excessive coughing and ...

Chronic obstructive pulmonary disease is one of the world’s leading causes of death - more than 300 million live with the ...

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a prescription drug used to treat COPD. With COPD, you have lung damage that worsens over time ...

Since the opening of that first clinic in rural Maryland, they’ve opened 10 others, including the first-ever pulmonary rehab ...

There are several tests that doctors can use to diagnose and monitor COPD. Let's take a look at what abnormal values for ...

Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA). The drug ...

Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD exacerbations in some patients whose symptoms aren’t adequately controlled with inhaled medicines.

The company has said it expects the target COPD patient population eligible ... Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to generate more than 21 billion euros ...

The decision could significantly expand use of what is already one of the industry’s best-selling ... pulmonary disease, or COPD, that can’t be controlled with other medications.

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses the potential of tailored treatment strategies and the importance of smoking cessation.

For the 16 million Americans with chronic obstructive pulmonary disease (COPD), travel can be as anxiety ... In this plan, you'll take actions and use the medications and therapies specific ...